Metabolic and Hemodynamic Alterations

Hyperglycemia-driven mechanisms:

1. Non-enzymatic glycation:
   • Glucose reacts with lysine and arginine residues on proteins → advanced glycation end products (AGEs)
   • AGEs accumulate in basement membrane and mesangial matrix
   • AGE-RAGE (receptor for AGE) interaction → inflammatory cascade (NF-κB activation, cytokine production)
2. Polyol pathway activation:
   • Glucose → sorbitol (via aldose reductase) → fructose
   • Sorbitol accumulation → osmotic stress, ROS generation
   • Depletes NADPH (essential for antioxidant defense)
3. PKC (protein kinase C) activation:
   • Hyperglycemia → DAG (diacylglycerol) → PKC overactivation
   • PKC phosphorylates multiple substrates → vascular permeability ↑, NADPH oxidase activation
   • Results in increased VEGF (vascular endothelial growth factor), reduced endothelial NO
4. ROS (reactive oxygen species) overproduction:
   • NADPH oxidase, mitochondrial oxidative phosphorylation overactivation
   • ROS cause oxidative stress → lipid peroxidation, protein damage
   • Overwhelms antioxidant defenses (SOD, catalase)

Hemodynamic Changes

Initial phase (hyperfiltration): - Hyperglycemia → afferent and efferent arteriolar vasodilation (but afferent > efferent) - Net: Increased glomerular capillary pressure → hyperfiltration - Hyperfiltration phase: GFR elevated (>120-140 mL/min/1.73 m²) despite normal baseline - Single-nephron GFR increased by 50-100% - Results in increased protein filtration (even “normal” filtered protein load exceeds tubular reabsorption capacity)

Progressive phase: - Persistent hyperglycemia → glomerulosclerosis (see pathology below) - Progressive loss of glomerular permselectivity - Hemodynamic injury compounds protein accumulation → further mesangial expansion - Efferent arteriolar constriction (from RAAS activation) becomes problematic; ACE-I/ARB block efferent vasoconstriction → improve outcomes [1]

Structural Changes: Pathology

Light microscopy: - Diffuse diabetic glomerulosclerosis: Thickening of glomerular basement membrane (>400 nm; normal ~350 nm) - Mesangial expansion: PAS+ (periodic acid-Schiff positive) matrix accumulation; nodular or diffuse - Kimmelstiel-Wilson nodules: Pathognomonic; nodular mesangial sclerosis with peripheral capillary sparing (also called diabetic nodules) - Hyaline arteriolosclerosis: Homogeneous hyaline material in afferent arteriole walls - Capillary wall collapse: Glomerular atrophy in advanced disease

Electron microscopy: - GBM thickening: >400 nm (diagnostic cutoff) - Mesangial matrix expansion - No electron-dense deposits (distinguishes from immune-complex GN)

Immunofluorescence: - No immune deposits (negative IF; diagnostic—differentiates DKD from GN or lupus) - Rare cases: IgM/C3 in areas of nodular disease (non-specific)

Progression Mechanisms: From Albuminuria to GFR Decline

Albuminuria initiates: 1. Protein filtration overloads reabsorptive capacity 2. Proteinuria → tubular epithelial cell injury (via receptor-mediated endocytosis) 3. Tubular damage → inflammatory recruitment → interstitial fibrosis

Interstitial fibrosis perpetuates decline: - Chronic inflammation from proteinuria, immune activation, hypoxia - Epithelial-mesenchymal transition (EMT): Tubular cells → fibroblasts - Myofibroblast activation → collagen deposition - Progressive tubular atrophy

Albuminuria as prognostic marker: - Microalbuminuria (30-300 mg/day): Increased GFR decline risk but not inevitable - Macroalbuminuria (>300 mg/day): Strong predictor of GFR decline (annual GFR decline 10-20 mL/min/1.73 m²/year if untreated) - Proteinuria reduction: Each 50% reduction in proteinuria associated with ~20-30% slowing of GFR decline [1]

Natural History Stages (Mogensen Classification)

Course variable: Not all diabetics with microalbuminuria progress; with modern management (RAAS blockade, SGLT2i, glycemic control), progression slowed substantially [1].

Clinical Presentation

Asymptomatic (most common): - Incidental proteinuria on routine urinalysis - Elevated Cr on basic metabolic panel (often mild initially) - Discovered during screening in diabetics

Symptomatic (if advanced): - Edema (nephrotic-range proteinuria → hypoalbuminemia → fluid retention) - Dyspnea (pulmonary edema from volume overload or CHF) - Fatigue, nausea (uremia) - Visual symptoms (diabetic retinopathy often coexists) - Neuropathy symptoms (diabetic peripheral neuropathy common)

Diagnosis

Clinical diagnosis (no biopsy needed if retinopathy present): - Diabetes (type 1 or 2) with adequate duration (usually >5 years for type 1; any duration for type 2) - Albuminuria (microalbuminuria or macroalbuminuria) - Diabetic retinopathy present: Highly specific for DKD; biopsy unnecessary [1] - GFR decline expected for DKD (not rapid, not sudden)

Kidney biopsy indications: - NO diabetic retinopathy (raises suspicion for non-diabetic GN as primary/concurrent) - Rapid GFR decline (>5 mL/min/1.73 m²/year) — suggests alternative etiology - Active urinary sediment: RBC casts, dysmorphic RBCs (suggests GN, not DKD) - Normal/low complement levels (post-infectious GN, lupus, MPGN, not DKD) - Systemic symptoms (rash, arthralgia, constitutional — lupus, vasculitis)

Differential diagnosis to exclude: - Acute kidney injury (hypovolemia, contrast nephropathy, sepsis) - Acute glomerulonephritis (lupus, ANCA, post-infectious) - Acute interstitial nephritis (medications) - Renal artery stenosis (especially if HTN difficult to control) - Urinary tract obstruction [1]

Pillar 1: RAAS Blockade (ACE Inhibitors or ARBs)

Mechanism: - ACE inhibitors: Block ACE → reduce angiotensin II → efferent arteriolar vasodilation → reduced glomerular pressure - ARBs: Block angiotensin II receptor 1 → similar efferent vasodilation - Both reduce proteinuria by 20-50% independent of blood pressure lowering

Evidence: - Landmark trials (Collaborative Study Group, MICRO-HOPE) show ACE-I/ARB slow DKD progression by ~30-50% - Recommended as first-line therapy for DKD with albuminuria [1]

Dosing: - ACE-I (lisinopril, enalapril, ramipril): titrate to max tolerated dose - ARB (losartan, valsartan, irbesartan): titrate to max tolerated dose - Avoid: Dual ACE-I + ARB (increased K+ and Cr without benefit; avoid)

Monitoring: - Check Cr, potassium 1-2 weeks post-initiation - Expect mild Cr increase (<20-30%) initially (afferent vasodilation reduces GFR transiently) - Target SBP <120 mmHg (SPRINT trial; modified to <130 in diabetics with albuminuria)

Pillar 2: SGLT2 Inhibitors (Game-Changing)

Mechanism: - SGLT2 (sodium-glucose cotransporter 2) in proximal tubule reabsorbs glucose - SGLT2i blocks reabsorption → increased urinary glucose → osmotic diuresis - Reduces proximal tubule reabsorption of sodium → decreased single-nephron GFR → reduced glomerular hyperfiltration - Also: Reduces weight, improves glycemic control, reduces BP, anti-inflammatory

Landmark trials: - DAPA-CKD: Dapagliflozin in CKD (eGFR 25-75) with or without diabetes - 39% RRR in composite outcome (sustained ≥50% GFR decline, ESRD, renal/CV death) - Benefits in diabetic AND non-diabetic CKD - Benefits independent of A1C reduction [2] - CREDENCE: Canagliflozin in type 2 diabetes + CKD - 30% RRR renal/CV outcomes - EMPA-KIDNEY: Empagliflozin in CKD (mixed diabetic/non-diabetic) - 25% RRR major renal outcomes

Indications (KDIGO 2024): - Type 2 diabetes + CKD (any eGFR) OR - Type 1 diabetes + CKD with albuminuria (limited evidence but increasingly used) - Non-diabetic CKD with albuminuria [2]

Recommended as co-first-line with ACE-I/ARB (KDIGO 2024) [2]

Adverse effects: - Genital mycotic infections (10-15%) - Polyuria, increased thirst (osmotic diuresis) - DKA (diabetic ketoacidosis): Rare but serious; monitor in type 1 diabetes - Volume depletion (elderly, concurrent diuretic use)

Pillar 3: Glycemic Control

Target A1C: Individualized based on duration, complications, hypoglycemia risk

• Standard target: A1C 7-8% (KDIGO recommends individualization)
• Intensive targets (A1C <7): In early DKD without complications
• Relaxed targets (A1C 7-9): In advanced CKD, elderly, or high hypoglycemia risk
• Key concept: Tight glycemic control slows albuminuria development but does not reverse established albuminuria

Glycemic agents: - GLP-1 receptor agonists (semaglutide, liraglutide, dulaglutide): Reduce CV/renal events; promote weight loss - SGLT2 inhibitors (above) - Metformin: Adjust dosing when eGFR <30 (contraindicated if eGFR <15-20 due to lactic acidosis risk) - Insulin: As needed for glycemic control; requires close monitoring when GFR declines - Sulfonylureas, meglitinides: Require dose adjustment in CKD; hypoglycemia risk

Pillar 4: Blood Pressure Control

SBP target: <120 mmHg (SPRINT trial; modified to <130 in some guidelines)

• Aggressive BP control slows DKD progression
• Each 10 mmHg SBP reduction associated with ~8-10% lower renal event risk

Antihypertensive strategy: - ACE-I/ARB as base (RAAS blocking) - Add calcium channel blocker (amlodipine, diltiazem) OR thiazide/thiazide-like (HCTZ, chlorthalidone) - Add beta-blocker if ischemic heart disease/HF - Avoid NSAIDs (reduce GFR; increase K+)

Pillar 5: Finerenone (Non-Steroidal RAAS Antagonist)

Mechanism: - Selective aldosterone antagonist (unlike spironolactone, which is non-selective) - Blocks aldosterone signaling → reduces inflammation, fibrosis - FIDELITY analysis: Combined FIDELIO-DKD (type 2 DM, CKD) + FIGARO-DKD (type 2 DM, CKD, high CV risk) trials - 18% RRR composite renal outcome (sustained GFR decline, ESRD, renal death) - Benefits additive to ACE-I/ARB + SGLT2i

Indications: - Type 2 diabetes + CKD with albuminuria (usually ACE-I/ARB + SGLT2i already on board) - Consider if continued proteinuria or GFR decline despite above [1]

Monitoring: - Hyperkalemia risk (especially if eGFR <30); check K+ baseline, 1 month, then q3 months - Hold if K+ >5.5 mEq/L

2025–2026 update: - Combination with SGLT2i is now prospectively supported — CONFIDENCE (n=800; simultaneous finerenone + empagliflozin) reduced albuminuria more than either agent alone and was well tolerated (Agarwal et al., N Engl J Med 2025;393:533-543; NCT05254002). - Sudden-death benefit — the FINE-HEART pooled analysis (18,991 patients) showed finerenone reduced sudden death 19% (HR 0.81; 95% CI 0.67–0.98; p=0.034; Foà et al., J Am Coll Cardiol 2026, PMID 42233928). - Heart-failure indication — finerenone was FDA-approved for HF with LVEF ≥40% in July 2025 (FINEARTS-HF; Solomon et al., N Engl J Med 2024;391:1475-1485, PMID 39225278), extending its role beyond diabetic kidney disease.

Pillar 6: Other Cardio-Protective Agents

GLP-1 receptor agonists: - Reduce DKD progression - Also reduce CV events, weight, BP - Examples: Semaglutide (Ozempic), liraglutide (Victoza) - On dialysis (observational, not trial-grade): Landmark GLP-1 RA trials excluded dialysis patients, leaving no trial-based guidance for this population. A real-world propensity score-matched TriNetX US cohort (2013-2022; 1688 matched pairs of new GLP-1 RA vs DPP-4i users among T2DM dialysis patients) now suggests GLP-1 RA may be preferable to DPP-4i, with lower MACE (HR 0.88, 95% CI 0.78-0.99), all-cause mortality (HR 0.84, 0.72-0.99), MI (HR 0.84), heart failure (HR 0.87), and sepsis (HR 0.81) (Chen JJ et al., Clin Kidney J 2026, PMID 42436945). These are observational, propensity-matched findings — hypothesis-generating, not trial-grade evidence.

SGLT2i (re-emphasized): - Now recommended for type 2 AND type 1 DKD

Anemia of CKD

• Causes: EPO deficiency (reduced GFR), chronic inflammation, decreased RBC lifespan
• Target: Hgb 10-11.5 g/dL (higher targets not superior; may increase CV events)
• Treatment: ESA (erythropoiesis-stimulating agents) ± iron supplementation

CKD-Mineral and Bone Disease

• Phosphate retention, secondary PTH elevation, vitamin D deficiency
• Management: Phosphate binders, vitamin D, monitor PTH/phosphate (see CKD-MBD review)

Hypertension

• Target <120-130 SBP; use ACE-I/ARB as base (RAAS blocking)

Cardiovascular Disease

• DKD patients have markedly elevated CV risk (DM + CKD + albuminuria = triple risk)
• Aspirin for secondary prevention; statins standard
• Consider SGLT2i and GLP-1 RA for cardio-renal protection

Dyslipidemia

• Statins regardless of LDL (DKD patients at very high CV risk)
• Target LDL <70 mg/dL

Without retinopathy (biopsy indicated):